Company profile
Osler Diagnostics Limited
Osler Diagnostics
Lab-quality diagnostics for anyone, anywhere, at any time
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Capital Allotment Shares
CapitalSH01 | Transaction MzUyMzA1NjcyMWFkaXF6a2N4 | Paper/PDF filed
Published 29 May 2026 01:46
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
High-sensitivity, low-cost point of care testing for infection to combat antimicrobial resistance by reducing over-prescription of antibiotics
1 Apr 2022 to 31 Mar 2024
Antimicrobial resistance (AMR), is a healthcare emergency. It is estimated to cause 12,000 deaths in the UK and 700,000 globally, and is forecast by the WHO to cause 10 million annual deaths globally by 2050, with the same economic impact as the 2008-2009 global financial crisis. Whereas antibiotics must be prescribed to treats serious infections, the gro...
High sensitivity multiplex testing with a novel cardiac biomarker for rapid triage of acute chest pain patients enabling healthcare efficiencies and improved patient outcomes
1 Oct 2021 to 31 Dec 2022
Acute myocardial infarctions (AMI/heart attacks) are one of the most common causes of death throughout the developed world. Each year ~720,000 UK citizens attend an emergency department (ED) with acute chest pain (ACP), representing ~6% of ED visits. Whilst the majority will not be suffering an AMI, due to the life-threatening nature of these symptoms, al...
An innovative universal point-of-care diagnostic platform delivering cost-effective, high-sensitivity and multiplexed testing targeting rapid detection and diagnosis of sepsis
1 Jun 2020 to 30 Nov 2021
Sepsis, a dysregulated immune response to infection leading to organ failure, is the leading cause of preventable death in the UK. Annually there are ~250,000 sepsis cases resulting in 46,000 deaths at a cost of ~£1.5Bn to the NHS and ~£11Bn to the UK economy. Early detection and treatment of sepsis significantly improves patient outcomes, with \>50% redu...
Development of a small, low-cost, accurate and rapid Point-of-Care diagnostic platform, with primary application to critical cardiovascular markers
1 Nov 2018 to 31 Jan 2020
"We are developing the next generation of healthcare diagnostics. Our portable diagnostic device could be deployed in the hospital emergency department, ambulance, or doctor's office and be used to diagnose diseases in under 10 minutes, cheaply, accurately, and from a pinprick of blood; moreover, it could diagnose an ever-increasing range of diseases, and...
Oxford Impedance Diagnostics - operationalising a disruptive Point of Care platform
1 Jan 2018 to 30 Jun 2018
We are developing a point of care (POC) diagnostic device that can perform most of the tests a conventional laboratory does, but in a hand held device that can sit on a GPs desk. Not only small, the device will also be cheap, accurate, and comprehensive (as it can test for a huge range of conditions). With such a device, doctors could diagnose patients li...